Supernus Pharmaceuticals, Inc. (SUPN)
| Market Cap | 1.73B |
| Revenue (ttm) | 661.82M |
| Net Income (ttm) | 73.87M |
| Shares Out | 55.81M |
| EPS (ttm) | 1.32 |
| PE Ratio | 23.54 |
| Forward PE | 15.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 457,064 |
| Open | 31.37 |
| Previous Close | 31.76 |
| Day's Range | 30.12 - 31.94 |
| 52-Week Range | 25.53 - 40.28 |
| Beta | 0.90 |
| Analysts | Hold |
| Price Target | 36.00 (+15.87%) |
| Earnings Date | May 7, 2025 |
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN... [Read more]
Financial Performance
In 2024, Supernus Pharmaceuticals's revenue was $661.82 million, an increase of 8.94% compared to the previous year's $607.52 million. Earnings were $73.87 million, an increase of 5512.84%.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SUPN stock is "Hold." The 12-month stock price forecast is $36.0, which is an increase of 15.87% from the latest price.
News
Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
BOSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential securities law violations. Investors who have lost money in their...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
On Tuesday, Supernus Pharmaceuticals, Inc. SUPN revealed the topline data from the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD).
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada
MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission ...
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue gro...
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Exe...
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was well-tolerated with few adverse events SPN-820 is a ...
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC...
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this ...
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes ke...
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and comm...
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Execu...